PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy.

Mediators Inflamm · 2015 · PMC4465766 · PMID 26113782

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

showed a trendP = 0.065so close (0.05 < p ≤ 0.1)

In the IIIC group and rectum group, patients with low PPP1R12A RCN showed a trend toward poor RFS (IIIC: HR = 1.874, P = 0.065, rectum HR = 2.091, P = 0.056) (Figures 1(c) and 2(b) ). 3.3.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.